Scrip
Once-weekly Byetta better than Lantus in Phase III trial
22 July 2009
Malini Guha
Please Login to read the full article.
22 July 2009
Malini Guha
Lilly/Amylin's once-weekly version of the twice-daily injectable diabetes drug Byetta (exenatide) has been shown in a head-to-head Phase III trial, DURATION-3, to provide slightly improved glucose control, weight loss as opposed to weight gain, and a lower incidence of hypoglycaemia compared with...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
